Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | 4.28%25.6B | -0.53%16.82B | -4.06%8.3B | -8.56%32.73B | -10.77%24.55B | -7.41%16.91B | -3.42%8.65B | 17.84%35.8B | 28.61%27.51B | 36.45%18.26B |
| -Interest income | ---- | -11.49%49.01B | ---- | 7.70%108.63B | ---- | 17.93%55.37B | ---- | 90.94%100.87B | ---- | 137.29%46.96B |
| -Interest expense | ---- | 16.31%-32.19B | ---- | -16.64%-75.9B | ---- | -34.05%-38.46B | ---- | -189.87%-65.07B | ---- | -348.09%-28.69B |
| Net service income | 8.87%10.15B | 7.15%6.64B | 5.66%3.32B | 3.85%12.3B | 2.57%9.32B | 1.89%6.2B | 4.73%3.15B | 0.64%11.85B | 0.09%9.09B | -2.30%6.09B |
| -Service income | ---- | 5.91%8.64B | ---- | 4.16%16.27B | ---- | 2.66%8.16B | ---- | 3.25%15.62B | ---- | 0.43%7.95B |
| -Service charge | ---- | -1.99%-2B | ---- | -5.14%-3.97B | ---- | -5.16%-1.96B | ---- | -12.43%-3.77B | ---- | -10.50%-1.86B |
| Net income on financial instruments at fair value | -4.76%15.06B | 0.29%10.55B | -0.92%5.36B | 26.74%21.12B | 25.87%15.81B | 29.64%10.52B | 31.47%5.41B | 62.10%16.66B | 64.99%12.56B | 67.05%8.11B |
| Special items of operating revenue | -76.07%1.1B | -96.97%111M | -81.20%667M | -116.86%-296M | 18.93%4.61B | -16.99%3.67B | -13.40%3.55B | 243.64%1.76B | 1,345.15%3.87B | 5,709.21%4.42B |
| Operating revenue | -4.38%51.91B | -8.50%34.12B | -14.95%17.65B | -0.31%65.85B | 2.36%54.29B | 1.13%37.29B | 2.88%20.75B | 30.50%66.06B | 38.28%53.04B | 50.24%36.88B |
| Operating profit before deducting impairment | -4.38%51.91B | -8.50%34.12B | -14.95%17.65B | -0.31%65.85B | 2.36%54.29B | 1.13%37.29B | 2.88%20.75B | 30.50%66.06B | 47.11%53.04B | 50.24%36.88B |
| Impairment and provisions | -43.71%-2.95B | -82.08%-1.94B | -21.67%-876M | 0.96%-3.41B | 15.07%-2.05B | 20.74%-1.07B | -66.67%-720M | 3.82%-3.45B | 45.78%-2.42B | -23.74%-1.35B |
| -Impairment losses of other assets | -43.71%-2.95B | -82.08%-1.94B | -21.67%-876M | 0.96%-3.41B | 15.07%-2.05B | 20.74%-1.07B | -66.67%-720M | 3.82%-3.45B | 45.78%-2.42B | -23.74%-1.35B |
| Operating profit after deducting impairment | -6.27%48.96B | -11.17%32.18B | -16.27%16.77B | -0.27%62.44B | 3.19%52.24B | 1.96%36.23B | 1.48%20.03B | 33.11%62.61B | 49.33%50.62B | 51.47%35.53B |
| Operating expenses - after deducting impairment | -9.09%-24.87B | -4.46%-17.02B | 2.07%-7.49B | -3.03%-33.04B | 3.89%-22.8B | -5.43%-16.3B | -0.78%-7.65B | 1.93%-32.07B | 0.49%-23.72B | 4.15%-15.46B |
| -Employee compensation and benefits | ---- | -7.73%-9.9B | ---- | -1.34%-18.47B | ---- | -2.66%-9.19B | ---- | -1.21%-18.22B | ---- | -0.65%-8.95B |
| -Depreciation and impairment of property, machinery and equipment | ---- | -10.15%-955M | ---- | -12.50%-1.85B | ---- | -10.87%-867M | ---- | 23.69%-1.64B | ---- | 27.05%-782M |
| -Amortization and impairment of intangible assets | -35.71%-2.23B | -15.25%-1.27B | -21.63%-613M | -22.33%-2.24B | ---1.64B | -36.22%-1.1B | ---504M | -7.41%-1.83B | ---- | 1.58%-809M |
| -Special items of operating expenditure | -7.03%-22.64B | 4.69%-4.89B | 3.74%-6.88B | -1.11%-10.5B | 10.81%-21.16B | -4.54%-5.14B | 5.86%-7.14B | 4.29%-10.38B | 0.49%-23.72B | 7.96%-4.91B |
| Special items of operating profit | -35.71%-2.23B | ---- | -21.63%-613M | ---- | -656.27%-1.64B | ---- | -25,300.00%-504M | ---- | 455.42%295M | ---- |
| Operating profit | -21.35%21.86B | -23.94%15.16B | -27.02%8.67B | -3.75%29.4B | 2.22%27.8B | -0.72%19.93B | -2.24%11.88B | 113.05%30.54B | 172.56%27.2B | 173.82%20.07B |
| Share of profits of associates | 0.40%2.24B | 1.54%1.65B | 5.72%813M | 3.74%2.91B | 2.67%2.23B | 2.72%1.63B | 4.91%769M | 3.08%2.81B | 7.09%2.18B | 9.25%1.58B |
| Special items of earning before tax | ---1B | ---1B | ---- | ---- | ---- | ---- | ---- | ---3B | ---- | ---- |
| Earning before tax | -23.07%23.11B | -26.66%15.81B | -25.03%9.48B | 6.46%32.31B | 2.25%30.03B | -0.47%21.56B | -1.83%12.65B | 77.91%30.35B | 144.57%29.37B | 146.66%21.66B |
| Tax | 8.13%-5.16B | 13.42%-3.37B | -5.57%-1.91B | -26.27%-7.31B | -11.60%-5.62B | -8.51%-3.89B | 2.53%-1.81B | -615.57%-5.79B | -1,095.72%-5.03B | -2,474.83%-3.59B |
| After-tax profit from continuing operations | -26.50%17.94B | -29.57%12.44B | -30.15%7.57B | 1.79%25B | 0.32%24.41B | -2.25%17.67B | -1.71%10.84B | 51.14%24.56B | 110.02%24.34B | 102.34%18.07B |
| Earning After tax | -26.50%17.94B | -29.57%12.44B | -30.15%7.57B | 1.79%25B | 0.32%24.41B | -2.25%17.67B | -1.71%10.84B | 51.14%24.56B | 110.02%24.34B | 102.34%18.07B |
| Minority profit | -23.28%603M | -30.56%384M | -2.77%246M | -0.58%1.02B | 1.29%786M | -1.78%553M | -9.96%253M | 48.70%1.03B | 46.14%776M | 66.08%563M |
| Profits attributable to shareholders | -27.89%16.38B | -30.60%11.51B | -31.93%6.93B | 2.16%22.92B | 0.60%22.72B | -2.24%16.59B | -1.39%10.18B | 56.36%22.43B | 126.58%22.59B | 112.98%16.97B |
| Dividend per share | 9.80%0.56 | ---- | ---- | ---- | 18.60%0.51 | ---- | ---- | ---- | --0.43 | ---- |
| Basic earnings per share | -24.39%0.93 | -26.97%0.65 | -27.78%0.39 | 8.70%1.25 | 6.96%1.23 | 3.49%0.89 | 3.85%0.54 | 59.72%1.15 | 130.00%1.15 | 115.00%0.86 |
| Diluted earnings per share | -23.77%0.93 | -26.14%0.65 | -27.78%0.39 | 8.77%1.24 | 7.02%1.22 | 2.33%0.88 | 3.85%0.54 | 58.33%1.14 | 128.00%1.14 | 115.00%0.86 |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers LLP | -- | -- | -- | PricewaterhouseCoopers LLP | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.